Inventiva SA ADR (IVA) has released an update.
Inventiva SA ADR reported a 43.4% increase in revenues in 2023 and a cash runway lasting until the third quarter of 2024, buoyed by a licensing agreement with Hepalys and a successful EIB loan tranche. Despite a decrease in cash and cash equivalents due to accelerated clinical trials for their lanifibranor treatment in MASH/NASH, the company remains optimistic about upcoming clinical milestones. Inventiva is actively exploring financing and strategic options to sustain operations beyond the forecasted period.
For further insights into IVA stock, check out TipRanks’ Stock Analysis page.
